Lantheus Holdings, Inc. (LNTH)

業務介紹

Lantheus Holdings, Inc.（藍西斯控股公司）是一家在全球開發、製造和商業化診斷和治療產品，協助臨床醫師診斷和治療心臟、癌症和其他疾病。該公司提供DEFINITY（一種用於心臟超聲檢查的微泡超聲增強劑）、TechneLite（核醫學的鈈發生器）、Xenon-133（用於評估肺功能）、Neurolite（用於識別因中風而導致腦部血流受阻或減少的區域）、Cardiolite（一種可注射的Tc-99m標記成像劑）、Thallium-201（用於檢測心血管疾病）和Gallium-67（用於檢測各種感染和癌瘤）。該公司還提供AZEDRA（一種用於治療成人和兒童患者的放射治療劑）、自動骨掃描指數（用於計算前列腺癌的疾病負擔，通過量化骨掃描上的熱點）、鈷（Co 57，一種非藥用放射化學品）、RELISTOR（用於阿片類藥物引起的便秘）和PYLARIFY（用於可視化淋巴結、骨骼和軟組織轉移，以確定前列腺癌的復發和/或轉移是否存在）。此外，該公司還開發了flurpiridaz F 18（用於評估心臟血流）、1095（一種PSMA靶向碘-131標記的小分子）、LMI 1195（用於兒童和成人的神經母細胞瘤）、PYLARIFY AI（一種基於人工智能的醫療設備軟件，用於在前列腺癌中進行標準化定量評估PSMA PET/CT影像）和leronlimab（一種正在研究的人源化單克隆抗體）。該公司為放射藥房、分銷商、綜合交付網絡、醫院、診所和集團實踐提供服務。該公司與NanoMab Technology Limited、Bausch Health Companies, Inc.、GE Healthcare Limited、Curium、Bayer AG、CytoDyn Inc.、ROTOP、FUJIFILM、Regeneron Pharmaceuticals, Inc.和POINT Biopharma US Inc.等公司建立了戰略合作夥伴關係。該公司成立於1956年，總部位於麻薩諸塞州北比勒利卡。

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

公司網址

https://www.lantheus.com